Oclacitinib Maleate Tablet

HOW SUPPLIED: Containing 3.6 mg、5.4 mg or 16 mg of oclacitinib per tablet.

INDICATIONS: Be used to control pruritus and atopic dermatitis caused by canine atopic dermatitis.

Oclacitinib is a novel JAK and JAK1-dependent cytokines inhibitor with IC50 of 10-99nM (JAK) and 36-249nM (JAK1), respectively. Oclacitinib is a very potent JAK1 inhibitor, which also inhibits the function of JAK1-dependentcytokines in several anti-allergic, inflammatory and pruritus responses. It has little effect on cytokines that are not involved in activating JAK1. Oclacitinib administered orally at 0.4-0.6mg/kg twice daily is safe and effective for the treatment of itching due to allergic dermatitis. During treatment, the administration of oclacitinib alleviated itching within 24 hours, and in experiments, more than 70% of experimental animals (dogs) reduced their itching response by more than 50% by day 7.

Only be used for scientific research, not for humans and animals.